Press Releases C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.17 ^USD	-1.12%		-8.18%	+9.20%

Apr. 08	C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	CI
Mar. 18	C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum	Apr. 09	GL
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	Apr. 08	GL
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024	Mar. 06	AQ
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	Mar. 05	GL
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	Mar. 05	AQ
C4 Therapeutics : Corporate Presentation – March 2024	Mar. 04	PU
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	Mar. 04	GL
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	Mar. 04	AQ
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Feb. 22	GL
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines	Jan. 09	GL
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines	Jan. 09	AQ
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals	Jan. 04	GL
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals	Jan. 04	AQ
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	GL
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	AQ
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma	Dec. 12	GL
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma	Dec. 12	AQ
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)	Dec. 12	GL
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed, Refractory Multiple Myeloma	Nov. 29	AQ
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma	Nov. 28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Press Releases

Filters